ClinicalTrials.gg
CompletedNCT01827839Updated Oct 18, 2018Results posted

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

A Phase 3 interventional study of Herpes Zoster vaccine (GSK1437173A) in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 4 sites in 2 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Herpes Zoster by GlaxoSmithKline — 3 open to participants now, 5 under way, 1 of them phase 3. Herpes Zoster · GlaxoSmithKline.

Enrollment
32nd of 37
96 · median 450
Started
2013
with 7 others
Phase 3
25 of 44
none open now
Registered
19th of 44
by date

Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 32nd largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2013, is one of 25 in phase 3, and was the 19th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

3 of the 44 studies in Herpes Zoster by GlaxoSmithKline are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Herpes Zoster by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ). The data collected will be compared with the data from subjects without HZ in other HZ/su trials.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Adults
  • Safety
  • Immunogenicity
  • Zoster
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a physician-documented history of HZ.
  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female aged 50 years or older at the time of the first vaccination.
  • Written obtained from the subject.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Active Herpes Zoster infection (a case is considered no more active when all lesions have at least turned to crusts).
  • Use of any or non-registered product other than the study vaccine/product within 30 days preceding the first dose of study vaccine/product, or planned use during the study period.
  • Chronic administration (defined as > 14 consecutive days) of or other immune-modifying drugs within six months prior to the first vaccine dose. For , a prednisone dose of \<20 mg/day, or equivalent, is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
  • Administration of long-acting immune-modifying drugs within six months prior to the first vaccine dose or expected administration at any time during the study period.
  • Administration or planned administration of a in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Previous vaccination against VZV or HZ and/or planned administration during the study of an HZ vaccine other than the study vaccine.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy.
  • History of any reaction or likely to be exacerbated by any component of the vaccine/product.
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C /100.4°F on rectal route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
  • Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions before Month 4 (i.e. 2 months after the last dose of study vaccine).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    HZ Group

    Subjects will receive 2 doses of the HZ/su vaccine at Month 0 and Month 2.

    Biological: Herpes Zoster vaccine (GSK1437173A)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA

    Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for anti-gE \[4x97 milli-international units per milliliter (mIU/mL)\]; For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

    Time frame: At Month 3

  2. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: Within 7 days (Day 0-6) after each vaccine dose and across doses

  3. Number of Days With Solicited Local Symptoms

    The number of days with any local symptoms during the solicited post-vaccination period.

    Time frame: Within 7 days (Day 0-6) after each vaccine dose

  4. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal (nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: Within 7 days (Day 0-6) after each vaccine dose and across doses

  5. Number of Days With Solicited General Symptoms

    The number of days with general symptoms during the solicited post-vaccination period.

    Time frame: Within 7 days (Day 0-6) after each vaccine dose

  6. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: Within 30 days (Days 0-29) after each vaccination

  7. Number of Subjects With Any Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From first vaccination up to 30 days post last vaccination

  8. Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From first vaccination up to 30 days post last vaccination

Secondary outcomes

  1. Anti-gE Antibody Concentrations

    Anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The outcome was assessed in each of the following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, in terms of antibody concentrations.

    Time frame: At Month 0 and at Month 3

  2. Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value

    The cut-off value was 97 mIU/mL.

    Time frame: At Month 0 and at Month 3

  3. Number of Subjects With SAEs

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: Starting after 30 days post last vaccination until study end (i.e. Month 14)

  4. Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: Starting after 30 days post last vaccination until study end (i.e. Month 14)

07

Results

Posted Mar 7, 2017

Participant flow

Participant flow — Overall Study
MilestoneGSK1437173A Group
Started96
Completed93
Not completed3
Withdrew: Adverse event1
Withdrew: Consent withdrawal2

Outcome measures

PrimaryNumber of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA

Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for anti-gE \[4x97 milli-international units per milliliter (mIU/mL)\]; For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

Time frame:
At Month 3
Reported as:
Count of participants · Participants
Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA
ParticipantsGSK1437173A GroupGSK1437173A Group 50-59 YOAGSK1437173A Group 60-69 YOAGSK1437173A Group >=70 YOA
Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA74262622
PrimaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
Within 7 days (Day 0-6) after each vaccine dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsGSK1437173A Group
Any Pain, Dose 161
Grade 3 Pain, Dose 13
Any Redness, Dose 117
Grade 3 Redness, Dose 10
Any Swelling, Dose 112
Grade 3 Swelling, Dose 10
Any Pain, Dose 256
Grade 3 Pain, Dose 25
Any Redness, Dose 222
Grade 3 Redness, Dose 22
Any Swelling, Dose 213
Grade 3 Swelling, Dose 20
Any Pain, Across Doses70
Grade 3 Pain, Across Doses8
Any Redness, Across Doses31
Grade 3 Redness, Across Doses2
Any Swelling, Across Doses19
Grade 3 Swelling, Across Doses0
PrimaryNumber of Days With Solicited Local Symptoms

The number of days with any local symptoms during the solicited post-vaccination period.

Time frame:
Within 7 days (Day 0-6) after each vaccine dose
Reported as:
Median · Days
Number of Days With Solicited Local Symptoms
DaysGSK1437173A Group
Pain post-Dose 13.0 (2.0 to 4.0)
Pain post-Dose 23.0 (2.0 to 4.0)
Redness post-Dose 13.0 (1.0 to 4.0)
Redness post-Dose 22.5 (2.0 to 4.0)
Swelling post-Dose 13.0 (1.5 to 4.5)
Swelling post-Dose 22.0 (2.0 to 3.0)
PrimaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal (nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
Within 7 days (Day 0-6) after each vaccine dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsGSK1437173A Group
Any Fatigue, Dose 137
Related Fatigue, Dose 129
Grade 3 Fatigue, Dose 15
Any Gastrointestinal, Dose 114
Related Gastrointestinal, Dose 16
Grade 3 Gastrointestinal, Dose 11
Any Headache, Dose 122
Related Headache, Dose 115
Grade 3 Headache, Dose 11
Any Myalgia, Dose 125
Related Myalgia, Dose 121
Grade 3 Myalgia, Dose 15
Any Shivering, Dose 115
Related Shivering, Dose 114
Grade 3 Shivering, Dose 12
Any Temperature/(Oral), Dose 17
Related Temperature/(Oral), Dose 16
Grade 3 Temperature/(Oral), Dose 10
Any Fatigue, Dose 241
Related Fatigue, Dose 228
Grade 3 Fatigue, Dose 26
Any Gastrointestinal, Dose 213
Related Gastrointestinal, Dose 26
Grade 3 Gastrointestinal, Dose 22
Any Headache, Dose 229
Related Headache, Dose 220
Grade 3 Headache, Dose 23
Any Myalgia, Dose 227
Related Myalgia, Dose 223
Grade 3 Myalgia, Dose 22
Any Shivering, Dose 225
Related Shivering, Dose 221
Grade 3 Shivering, Dose 25
Any Temperature/(Oral), Dose 214
Related Temperature/(Oral), Dose 211
Grade 3 Temperature/(Oral), Dose 20
Any Fatigue, Across Doses57
Related Fatigue, Across Doses43
Grade 3 Fatigue, Across Doses10
Any Gastrointestinal, Across Doses23
Related Gastrointestinal, Across Doses11
Grade 3 Gastrointestinal, Across Doses2
Any Headache, Across Doses37
Related Headache, Across Doses28
Grade 3 Headache, Across Doses4
Any Myalgia, Across Doses35
Related Myalgia, Across Doses31
Grade 3 Myalgia, Across Doses6
Any Shivering, Across Doses31
Related Shivering, Across Doses26
Grade 3 Shivering, Across Doses7
Any Temperature/(Oral), Across Doses19
Related Temperature/(Oral), Across Doses15
Grade 3 Temperature/(Oral), Across Doses0
PrimaryNumber of Days With Solicited General Symptoms

The number of days with general symptoms during the solicited post-vaccination period.

Time frame:
Within 7 days (Day 0-6) after each vaccine dose
Reported as:
Median · Days
Number of Days With Solicited General Symptoms
DaysGSK1437173A Group
Fatigue post-Dose 12.0 (1.0 to 4.0)
Fatigue post-Dose 22.0 (1.0 to 3.0)
Gastrointestinal symptoms post-Dose 11.5 (1.0 to 3.0)
Gastrointestinal symptoms post-Dose 21.0 (1.0 to 2.0)
Headache post-Dose 12.0 (1.0 to 3.0)
Headache post-Dose 22.0 (1.0 to 3.0)
Myalgia post-Dose 13.0 (2.0 to 4.0)
Myalgia post-Dose 22.0 (1.0 to 3.0)
Shivering post-Dose 11.0 (1.0 to 2.0)
Shivering post-Dose 21.0 (1.0 to 2.0)
Temperature post-Dose 11.0 (1.0 to 1.0)
Temperature post-Dose 21.5 (1.0 to 2.0)
PrimaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
Within 30 days (Days 0-29) after each vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsGSK1437173A Group
Any AE(s)30
Grade 3 AE(s)11
Related AE(s)12
PrimaryNumber of Subjects With Any Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From first vaccination up to 30 days post last vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs)
ParticipantsGSK1437173A Group
Number of Subjects With Any Serious Adverse Events (SAEs)1
PrimaryNumber of Subjects With Any Potential Immune-mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From first vaccination up to 30 days post last vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)
ParticipantsGSK1437173A Group
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)0
SecondaryAnti-gE Antibody Concentrations

Anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The outcome was assessed in each of the following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, in terms of antibody concentrations.

Time frame:
At Month 0 and at Month 3
Reported as:
Geometric mean · mIU/mL
Anti-gE Antibody Concentrations
mIU/mLGSK1437173A Group 50-59 YOAGSK1437173A Group 60-69 YOAGSK1437173A Group >=70 YOA
Anti-gE at Month 02561.4 (1531.4 to 4284.2)2083.5 (1357.4 to 3198.0)2600.6 (1319.4 to 5125.9)
Anti-gE at Month 356413.7 (43783.3 to 72687.6)44470.8 (37373.2 to 52916.2)42642.5 (34698.8 to 52404.9)
SecondaryNumber of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value

The cut-off value was 97 mIU/mL.

Time frame:
At Month 0 and at Month 3
Reported as:
Count of participants · Participants
Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value
ParticipantsGSK1437173A Group 50-59 YOAGSK1437173A Group 60-69 YOAGSK1437173A Group >=70 YOA
Anti-gE at Month 0292825
Anti-gE at Month 3292825
SecondaryNumber of Subjects With SAEs

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
Starting after 30 days post last vaccination until study end (i.e. Month 14)
Reported as:
Count of participants · Participants
Number of Subjects With SAEs
ParticipantsGSK1437173A Group
Number of Subjects With SAEs2
SecondaryNumber of Subjects With Any Potential Immune-mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
Starting after 30 days post last vaccination until study end (i.e. Month 14)
Reported as:
Count of participants · Participants
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)
ParticipantsGSK1437173A Group
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)0

Adverse events

Collected over Serious Adverse Events were assessed throughout the study (up to Month 14). Other Adverse Events were assessed during the 30-day (Days 0-29) post-vaccination period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Group0/96 (0%)3/96 (3.1%)77/96 (80.2%)
Most frequent serious events
Most frequent serious events
EventGSK1437173A Group
Chronic gastritisGastrointestinal disorders1/96
Duodenal ulcer perforationGastrointestinal disorders1/96
Gastrooesophageal reflux diseaseGastrointestinal disorders1/96
PancreatitisGastrointestinal disorders1/96
CholecystitisHepatobiliary disorders1/96
Most frequent other events
Most frequent other events
EventGSK1437173A Group
PainGeneral disorders70/96
FatigueGeneral disorders57/96
HeadacheNervous system disorders37/96
MyalgiaMusculoskeletal and connective tissue disorders35/96
ChillsGeneral disorders31/96
ErythemaSkin and subcutaneous tissue disorders31/96
Gastrointestinal disorderGastrointestinal disorders23/96
PyrexiaGeneral disorders19/96
SwellingGeneral disorders19/96

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A Group
Mean64.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A Group
Female63
Male33
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A Group
White - Caucasian/European92
Asian - Central/South Asian2
Asian - Japanese1
White - Arabic /North African1
08

Study locations

4 sites
  • GSK Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • GSK Investigational Site
    Barnaul, 656056, Russian Federation
  • GSK Investigational Site
    Ekaterinburg, 620137, Russian Federation
09

References and documents

Publications

  • Godeaux O, Kovac M, Shu D, Grupping K, Campora L, Douha M, Heineman TC, Lal H. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults >/= 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial. Hum Vaccin Immunother. 2017 May 4;13(5):1051-1058. doi: 10.1080/21645515.2016.1265715. Epub 2017 Jan 9. PubMed 28068212 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Feb 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 3 years after primary completion. A results delay was requested in May 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2013
First posted
Apr 10, 2013
Start
Jun 10, 2013
Primary completionActual
Feb 10, 2014
CompletionActual
Nov 25, 2014
Results delay requested
May 29, 2014
Results first posted
Mar 7, 2017
Last update
Oct 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01827839
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 10, 2013
Start date
Jun 10, 2013
Primary completion
Feb 10, 2014
Completion
Nov 25, 2014
Results posted
Mar 7, 2017
Last update
Oct 18, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Herpes Zoster Vaccine

Start the discussion